Company Description
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications.
The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2001 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 50 |
CEO | Stephen Yoder |
Contact Details
Address: 225 Franklin Street, 26th Floor Boston, Massachusetts 02110 United States | |
Phone | 857 246 8998 |
Website | pieris.com |
Stock Details
Ticker Symbol | PIRS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001583648 |
CUSIP Number | 720795103 |
ISIN Number | US7207951036 |
Employer ID | 30-0784346 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Stephen S. Yoder J.D. | Chief Executive Officer, President and Director |
Thomas Bures | Senior Vice President, Chief Financial Officer and Treasurer |
Dr. Shane Olwill Ph.D. | Senior Vice President and Chief Development Officer |
Maria Kelman | Executive Director of Investor Relations |
Prompong Chaikul | Chief Supply Chain Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 14, 2024 | 10-Q | Quarterly Report |
Aug 9, 2024 | S-4 | Filing |
Aug 8, 2024 | 425 | Filing |
Aug 8, 2024 | 8-K | Current Report |
Aug 7, 2024 | SCHEDULE 13G | Filing |
Aug 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jul 24, 2024 | 425 | Filing |
Jul 24, 2024 | 8-K | Current Report |
Jul 3, 2024 | 8-K | Current Report |
May 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |